Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Chronogyn: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Chronogyn - General Information

A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Chronogyn has been used in the treatment of endometriosis and some benign breast disorders.

 

Pharmacology of Chronogyn

Chronogyn is a derivative of the synthetic steroid ethisterone, a modified testosterone. It was approved by the U.S. Food and Drug Administration (FDA) as the first drug to specifically treat endometriosis, but its role as a treatment for endometriosis has been largely replaced by the gonadotropin-releasing hormone (GnRH) agonists. Chronogyn has antigonadotropic and anti-estrogenic activities. Chronogyn acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties.

 

Additional information about Chronogyn

Chronogyn Indication: For the treatment of endometriosis and some benign breast disorders. Mechanism Of Action: As a gonadotropin inhibitor, danazol suppresses the pituitary-ovarian axis possibly by inhibiting the output of pituitary gonadotropins. Chronogyn also depresses the preovulatory surge in output of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) and therefore reduces ovarian estrogen production. Chronogyn also may directly inhibit ovarian steroidogenesis, bind to androgen, progesterone, and glucocorticoid receptors, bind to sex-hormone-binding globulin and corticosteroid-binding globulin, and increase the metabolic clearance rate of progesterone. Endometriosis - As a consequence of suppression of ovarian function, both normal and ectopic endometrial tissues become inactive and atrophic. As a result, anovulation and associated amenorrhea occur. Fibrocystic breast disease - The exact mechanism of action is unknown, but may be related to suppressed estrogenic stimulation as a result of decreased ovarian production of estrogen. A direct effect on steroid receptor sites in breast tissue also is possible. Disappearance of nodularity, relief of pain and tenderness, and possibly changes in the menstrual pattern result. Hereditary angioedema - Chronogyn corrects the underlying biochemical deficiency by increasing serum concentrations of the deficient C1 esterase inhibitor, resulting in increased serum concentrations of the C4 component of the complement system. (Source: PharmGKB) Drug Interactions: Anisindione The androgen increases the anticoagulant effect Cyclosporine The androgen increases the anticoagulant effect Carbamazepine Increases the effect of carbamazepine Dicumarol The androgen increases the anticoagulant effect Acenocoumarol The androgen increases the anticoagulant effect Warfarin The androgen increases the anticoagulant effect Lovastatin Risk of severe myopathy/rhabdomyolysis with this combination Tacrolimus Increases the effect and toxicity of tacrolimus Food Interactions: Take without regard to meals. Generic Name: Danazol Synonyms: Not Available Drug Category: Estrogen Antagonists Drug Type: Small Molecule; Approved Other Brand Names containing Danazol: Anatrol; Chronogyn; Cyclomen; Danocrine; Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Hepatic, to principal metabolites, ethisterone and 17-hydroxymethylethisterone. Half Life: Approximately 24 hours. Dosage Forms of Chronogyn: Capsule Oral Capsule Oral Chemical IUPAC Name: Not Available Chemical Formula: C22H27NO2 Danazol on Wikipedia: https://en.wikipedia.org/wiki/Danazol Organisms Affected: Humans and other mammals